WEST HOLLYWOOD, Calif. and RAMAT EFAL, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- VisionWave Holdings, Inc. (“VisionWave”) (NASDAQ: VWAV) today announced that announced that, following the recently announced Letter of Intent pursuant to which VisionWave has agreed, subject to closing conditions, to acquire Solar Drone Ltd. (a wholly-owned subsidiary of BladeRanger Ltd.), Shmulik Yannay, Chief Executive Officer of Solar Drone Ltd., is currently in Greece conducting a series of technical meetings and presentat ...

Core Insights - Gelteq Limited announced positive preclinical results indicating its proprietary gel formulation achieved significantly higher bioavailability compared to a leading antihistamine product [1][2] - The formulation demonstrated a 38–45% increase in systemic exposure and absorption, along with higher peak concentrations while maintaining a comparable time to peak plasma concentration [2][3] - The results validate Gelteq's platform for enhancing the performance of established drugs and open opportunities for a broader portfolio of pharmaceutical applications [3][4] Company Overview - Gelteq is a clinical and science-based company based in Melbourne, Australia, focused on developing gel-based oral delivery solutions for various applications including prescription drugs and nutraceuticals [5] - The proprietary formulation technology aims to address challenges in conventional drug delivery such as taste masking and swallowing difficulties [5] Strategic Implications - The positive results support the company's strategy to partner and develop gel-based formulations across a wide range of therapeutically relevant compounds, potentially expanding beyond the antihistamine market [4] - The company plans to pursue FDA approval for an antihistamine product and engage with pharmaceutical partners interested in next-generation drug delivery formats [4]

Core Insights - Amaze Holdings, Inc. has launched a new Creator Studio in collaboration with Loft 100 Studios, providing creators with access to a professional production facility in Southern California [1][2][3] - The Creator Studio is designed to support both emerging and established creators in producing high-quality content, including product videos, TikToks, livestreams, and podcasts [2][3] - The studio features advanced production capabilities, including a large flexible production studio, a control room for live productions, and various professional equipment [6] Company Overview - Amaze Holdings, Inc. is a global leader in creator-powered commerce, offering tools for product creation, e-commerce solutions, and managed services [4] - The company aims to empower creators to sell products and connect with audiences, facilitating sustainable income through authentic experiences [4] Strategic Partnership - The partnership with Loft 100 Studios allows Amaze to provide creators with access to a proven production environment, enhancing their content quality and business growth potential [3] - The collaboration is expected to elevate the enterprise value of creators by providing them with the necessary tools and support [3]

Core Points - Science Applications International Corp. (SAIC) has been awarded a $242 million contract by the Naval Undersea Warfare Center Division, Newport to support the Propulsion Test Facility (PTF) for the U.S. Navy [1][2] - The contract is a 5-year follow-on agreement that emphasizes the U.S. Navy's trust in SAIC's capabilities in engineering, technical, and logistics support [2][3] - The contract will enable SAIC to provide testing, engineering, and technical services for various torpedo systems and unmanned underwater vehicles, ensuring the PTF meets emerging Navy research and development needs [3] Company Overview - SAIC is a Fortune 500 mission integrator focused on technology and innovation across defense, space, civilian, and intelligence markets [4] - The company has approximately 24,000 employees and annual revenues of about $7.5 billion [5]

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a Bitcoin+ Treasury company that builds a portfolio of frontier technology businesses ranging from high-performance energy systems to AI Robotics, today announced that it is developing a next-generation 400V battery system to support a Counter-UAS Directed Energy System, delivering a complete design package and prototype build in 5 weeks after receipt of the purchase order. The system is p ...

Core Viewpoint - Houston American Energy Corp. has successfully completed a registered direct offering, raising approximately $8 million at a price of $3.50 per share, indicating strong market confidence in the company's strategic direction towards renewable energy [1][2][3]. Financing Details - The offering was supported by Tier-1 institutional investors, reflecting confidence in the company's transition to circular fuels and renewable energy production [2]. - The net proceeds will be allocated to complete Phase 1 of the Cedar Port Renewable Energy Complex, advance the Final Investment Decision for a waste-plastics-to-fuels facility, repay a convertible note, and for general corporate purposes [2][3]. Strategic Growth - The CEO highlighted that this transaction is a significant milestone in the company's long-term growth strategy, enhancing its capital position and financial flexibility [3]. - Recent achievements include the groundbreaking of the Cedar Port Renewable Energy Complex and the integration of the circular-fuels platform acquired from Abundia Global Impact Group, which supports long-term value creation [3][6]. Regulatory Compliance - The securities were issued under an existing shelf registration statement effective from November 3, 2025, with a prospectus supplement filed with the SEC [4].

Core Insights - NeoVolta Inc. has announced a $13 million private placement financing led by Infinite Grid Capital to support its growth and manufacturing expansion in the U.S. [1][2] Financing and Manufacturing Initiative - The investment aims to provide immediate and future capital for NeoVolta's domestic manufacturing initiative, including a memorandum of understanding with third parties to establish a battery energy storage manufacturing facility in Georgia [2][3] - The proposed facility is designed for an initial annual capacity of approximately 2 GWh, focusing on utility-level and commercial & industrial battery energy storage systems, which will expand NeoVolta's market and revenue opportunities [3] Financial Position and Growth - The capital raised will significantly enhance NeoVolta's financial position, improving liquidity and addressing working capital needs to support ongoing growth initiatives [3] - NeoVolta and IGC plan to evaluate future commercial opportunities, including potential offtake arrangements that align with IGC's grid-scale pipeline [4] Strategic Partnership - The partnership with Infinite Grid Capital is seen as a long-term strategic investment, with IGC committing $10 million to support NeoVolta's manufacturing plans and commercial scaling [5] - Both companies will provide updates on key milestones and the evolution of NeoVolta's manufacturing and market initiatives as the relationship develops [5]

Core Insights - Biodexa Pharmaceuticals has activated its first European site for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP), marking a significant milestone in expanding treatment options for European patients [1][2] Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs, including eRapa for FAP and other therapies for type 1 diabetes and rare brain cancers [7] Clinical Trial Details - The Serenta trial is a randomized, double-blind, placebo-controlled study designed to assess the efficacy of eRapa in preventing disease progression in FAP patients, who face a near-100% risk of colorectal cancer by age 50 if untreated [3][4] - The trial began enrolling patients in the US in August 2025, with nine additional European sites expected to activate in the next 2-3 months across the Netherlands, Spain, Denmark, and Italy [3] Treatment Context - FAP is a rare inherited disorder characterized by the development of numerous colorectal polyps, leading to a significant unmet need for effective, less invasive therapies, as current standard care involves surgical resection [4] - eRapa, a proprietary oral formulation of rapamycin, is an mTOR inhibitor that targets the over-expression of mTOR in FAP polyps, providing a rationale for its use in treatment [5][8] Funding and Support - The advancement of the Serenta trial has been supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas, alongside collaborations with Emtora Biosciences and Precision for Medicine [2][6]

BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego, CA. Presentation details are as follows: Poster Presentation Date & Time: Wednesda ...

Core Insights - Waton Financial Limited has announced an expanded strategic partnership with Panda AI to explore the formation of a joint venture, enhancing their collaboration in AI-driven securities trading [1][2][3] - The partnership aims to leverage Panda AI's capabilities to improve Waton's DePearl™ core AI technology and trading agents, promoting automated trading strategies globally [1][2] - This collaboration is expected to strengthen Waton's position as a key infrastructure provider in the AI trading economy, creating new revenue opportunities and enhancing institutional client engagement [2][3] Company Overview - Waton Financial Limited operates primarily through its subsidiaries in Hong Kong, offering a range of financial services including securities brokerage, asset management, and software licensing [4] - The company emphasizes a technology-driven and customer-centric approach to deliver innovative financial solutions [4] Strategic Goals - The partnership with Panda AI reflects Waton's commitment to transforming traditional finance through AI, aiming for institutional-scale adoption of AI trading solutions [3] - The potential joint venture may expand Waton's AI product offerings, including the InfoMan investor relations agent, reinforcing its competitive edge in the fintech sector [3]